Thus, the aforementioned results suggested that a concurrent exposure to CB1 and CB2 agonists—especially at the ratio of 2:1—considerably enhanced the cytotoxic effects on breast cancer MDA-MB-231 cells. Here, CNR1 is linked to breast carcinoma.